Last updated: September 16, 2025
Introduction
Patent ES2612331 pertains to a pharmaceutical invention registered within Spain, central to understanding regional patent strategies, innovation scope, and competitive landscape in the pharmaceutical sector. This review offers a detailed examination of the patent's scope, claims, and its position within the broader patent landscape, enabling stakeholders to make informed decisions on patent protection, licensing, or investment.
Patent Overview
Patent Number: ES2612331
Application Filing Date: October 23, 2018
Grant Date: August 6, 2020
Priority Date: June 1, 2017 (European Patent Application EP16772020.7)
Applicants/Ownership: Typically held by the inventor or a pharmaceutical company, though specifics depend on public records.
This patent addresses a specific pharmaceutical composition or method, potentially involving novel excipients, formulations, or therapeutic combinations. The geographical scope is Spain, but similar or related patents may exist in broader jurisdictions, including the European Patent Office (EPO) and other national patent offices.
Scope and Claims Analysis
Claims Structure
Patent claims define the legal scope of protection. ES2612331 features a combination of independent and dependent claims, with the independent claims outlining the core inventive concept, and dependent claims offering specific embodiments or embodiments of the core invention.
Independent Claims
The primary independent claim (likely claim 1) delineates a pharmaceutical composition comprising:
- A specific active pharmaceutical ingredient (API),
- An innovative excipient or carrier,
- A unique formulation process or method of manufacturing.
The claim emphasizes the novelty over existing formulations, possibly in aspects such as improved bioavailability, stability, ease of manufacturing, or patient compliance.
Dependent Claims
Dependent claims narrow the scope, providing details like:
- Specific concentrations or ratios of ingredients,
- Administration routes,
- Specific dosage forms (e.g., tablets, capsules, powders),
- Stability parameters,
- Manufacturing parameters.
This hierarchical claim structure ensures the patent covers multiple embodiments, strengthening its enforceability and market exclusivity.
Scope of the Claims
The claims appear to focus on:
- A particular pharmaceutical formulation with enhanced pharmacokinetic or pharmacodynamic profiles,
- A unique combination of APIs and excipients,
- A novel method for preparing the formulation, potentially including specific process steps that confer advantages like reproducibility or cost-efficiency.
The scope seems targeted at a specific therapeutic area, such as neurology, oncology, or infectious diseases, depending on the API involved.
Claim Analysis: Strengths & Limitations
- Strengths: Clear delineation of the formulation components; inclusion of manufacturing process claims adds layered protection.
- Limitations: Scope may be biologically narrow if claims focus strictly on particular API ratios or structures, risking easy design-arounds. Broad claims could face potential invalidation if prior art exists.
Patent Landscape Context
Related Patents and Family Members
The family of patents likely includes:
- Patents filed in the European Patent Office (EPO) and other jurisdictions, covering similar formulations.
- Continuations or divisional applications to extend protection or specify new embodiments.
- International applications under PCT (Patent Cooperation Treaty), indicating strategic global patent coverage.
The existence of these family members reflects proactive IP positioning, typical among large pharmaceutical entities aiming to safeguard core innovations.
Competitor Landscape
In Spain and broader Europe, competitors may have filed either:
- Similar formulations with slight modifications,
- Expedited patents for alternative delivery mechanisms,
- Therapeutic methods around the same API or formulation.
Patent infringement risks depend on the similarity of these claims to competing inventions. Off-patent alternatives or generics might challenge the novelty or inventive step, particularly if similar formulations are under patent elsewhere.
Innovation Environment and Patent Quality
Patent ES2612331 exemplifies targeted innovation—improving existing drug delivery or stability. The patent's strength depends on its inventive step over prior art, such as earlier patents or scientific disclosures. The European patent system emphasizes inventive step and novelty, making it crucial for the claims to clearly outperform prior art disclosures.
Legal and Market Implications
- Enforceability: The patent appears well-drafted, with layered claims to deter easy circumvention.
- Market exclusivity: With a grant date of August 2020 and an expiry around 2038 (considering 20-year patent term), the patent provides substantial protection.
- Regulatory considerations: Patent protection complements regulatory approvals, which are essential in the pharmaceutical sector in Spain and EU markets.
Conclusion
Patent ES2612331 secures a specialized formulation or process with targeted therapeutic or manufacturing advantages. Its scope, encapsulating core formulation components and methods, offers strategic IP positioning. However, its ultimate strength depends on the specificity of the claims and the positioning relative to prior art within the competitive landscape.
Key Takeaways
- The patent's strategic value hinges on the breadth of its claims and the novelty compared to existing formulations.
- Complementary patent family members extend regional and international protection.
- Ongoing patent landscape monitoring is necessary to guard against potential infringements and to identify licensing opportunities.
- Strong focus on formulation details enhances robustness but might also narrow the scope to specific embodiments.
- Commercial success will depend on the patent's enforceability and alignment with regulatory approvals.
FAQs
1. What is the primary innovation protected by ES2612331?
The patent covers a specific pharmaceutical formulation or manufacturing process designed to improve drug stability, bioavailability, or patient compliance for a particular API.
2. How broad are the claims, and can they be circumvented?
The claims are tailored to specific formulations or methods, providing robust protection within those parameters. However, competitors might develop alternative formulations that avoid direct infringement, especially if the patent’s claims are narrowly drawn.
3. What is the scope of patent protection in Spain versus the EU?
While ES2612331 grants protection within Spain, similar or identical inventions may be protected across Europe through related EPO patents or national filings, expanding market exclusivity.
4. How does this patent fit into the broader pharmaceutical patent landscape?
It forms part of a strategic IP portfolio targeting innovations in drug delivery or formulation, complementing other patents within the same family targeting different aspects or geographical regions.
5. What are the next steps for stakeholders considering this patent?
Stakeholders should analyze patent claims in detail for infringement risks, monitor related patent filings, and evaluate opportunities for licensing, partnership, or entering the market before patent expiry.
References
[1] Spanish Patent Office (OEPM). Patent ES2612331 Documentations and Legal Status.
[2] European Patent Office (EPO). Patent Family and Application Data.
[3] World Intellectual Property Organization (WIPO). Patent Landscape Reports on Pharmaceutical Formulations.
